Tami Rashal

1.3k total citations
31 papers, 639 citations indexed

About

Tami Rashal is a scholar working on Molecular Biology, Cancer Research and Hematology. According to data from OpenAlex, Tami Rashal has authored 31 papers receiving a total of 639 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Molecular Biology, 6 papers in Cancer Research and 5 papers in Hematology. Recurrent topics in Tami Rashal's work include Nuclear Structure and Function (24 papers), Cancer, Lipids, and Metabolism (6 papers) and Acute Myeloid Leukemia Research (3 papers). Tami Rashal is often cited by papers focused on Nuclear Structure and Function (24 papers), Cancer, Lipids, and Metabolism (6 papers) and Acute Myeloid Leukemia Research (3 papers). Tami Rashal collaborates with scholars based in United States, Denmark and Canada. Tami Rashal's co-authors include Sharon Shacham, Michael Kauffman, Morten Mau‐Sørensen, Nashat Gabrail, Thaddeus J. Unger, Robert Carlson, Rachid Baz, Michael R. Savona, Martin Gutierrez and Yosef Landesman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Tami Rashal

30 papers receiving 637 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Tami Rashal	474	220	220	100	83	31	639
Yoshiaki Chinen	291 0.6×	143 0.7×	170 0.8×	134 1.3×	58 0.7×	49	513
Michelle F. Waldman	441 0.9×	265 1.2×	306 1.4×	92 0.9×	69 0.8×	14	653
Sanjiv Modi	245 0.5×	210 1.0×	242 1.1×	161 1.6×	183 2.2×	11	589
Sara Gandolfi	328 0.7×	172 0.8×	247 1.1×	66 0.7×	38 0.5×	28	491
M.V. Mateos	269 0.6×	286 1.3×	358 1.6×	132 1.3×	79 1.0×	15	557
Kai Hu	220 0.5×	130 0.6×	106 0.5×	74 0.7×	45 0.5×	59	456
Koorosh Korfi	228 0.5×	148 0.7×	241 1.1×	85 0.8×	151 1.8×	18	549
Yuji Shimura	357 0.8×	226 1.0×	227 1.0×	199 2.0×	100 1.2×	69	704
Prapti A. Patel	240 0.5×	156 0.7×	323 1.5×	37 0.4×	91 1.1×	60	532
Norihiro Awaya	203 0.4×	120 0.5×	204 0.9×	60 0.6×	122 1.5×	26	474

Countries citing papers authored by Tami Rashal

Since Specialization

Citations

This map shows the geographic impact of Tami Rashal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tami Rashal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tami Rashal more than expected).

Fields of papers citing papers by Tami Rashal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tami Rashal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tami Rashal. The network helps show where Tami Rashal may publish in the future.

Co-authorship network of co-authors of Tami Rashal

This figure shows the co-authorship network connecting the top 25 collaborators of Tami Rashal. A scholar is included among the top collaborators of Tami Rashal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tami Rashal. Tami Rashal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Baron, Szilvia, et al.. (2022). Selinexor, a selective inhibitor of nuclear export, inhibits human neutrophil extracellular trap formation in vitro. Frontiers in Pharmacology. 13. 1030991–1030991. 8 indexed citations

Lawrence, Yaacov Richard, Einat Shmueli, Noam Yarom, et al.. (2018). Nuclear Export Inhibition for Radiosensitization; a Proof-of-Concept Phase I Clinical Trial of Neoadjuvant KPT-330 Plus Chemoradiation in Locally Advanced Rectal Cancer. International Journal of Radiation Oncology*Biology*Physics. 102(3). e10–e10. 2 indexed citations

Kuruvilla, John, Michael R. Savona, Rachid Baz, et al.. (2017). Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 129(24). 3175–3183. 112 indexed citations

Vergote, Ignace, Bente Lund, Hanne Havsteen, et al.. (2016). Results of a phase 2 trial of selinexor, an oral selective inhibitor of nuclear export (SINE) in 114 patients with gynaecological cancers. Annals of Oncology. 27. vi296–vi296. 3 indexed citations

Baz, Rachid, Kenneth H. Shain, Melissa Alsina, et al.. (2016). Phase I trial of the combination of selinexor (SEL), liposomal doxorubicin (DOX) and dexamethasone (Dex) for relapsed and refractory multiple myeloma (RRMM).. Journal of Clinical Oncology. 34(15_suppl). 8013–8013. 10 indexed citations

Malafa, Mokenge P., Domenico Coppola, Kazim Husain, et al.. (2015). Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer. Molecular Cancer Therapeutics. 14(7). 1570–1581. 50 indexed citations

Rashal, Tami, Sivan Elloul, Marsha Crochiere, et al.. (2015). Abstract 4490: Selinexor (KPT-330) radio-sensitizes non-small cell lung cancer cells in vitro and in vivo. Cancer Research. 75(15_Supplement). 4490–4490. 1 indexed citations

Tan, David S.P., Wei Peng Yong, Ross A. Soo, et al.. (2015). Phase I study of the safety and tolerability of the Exportin 1 (XPO1) inhibitor Selinexor (SXR) in Asian patients (pts) with advanced solid cancers.. Journal of Clinical Oncology. 33(15_suppl). 2542–2542. 3 indexed citations

Lassen, Ulrik, Morten Mau‐Sørensen, Andrew L. Kung, et al.. (2015). A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM).. Journal of Clinical Oncology. 33(15_suppl). 2044–2044. 4 indexed citations

10.

Rubnitz, Jeffrey E., Raul C. Ribeiro, Boris Klebanov, et al.. (2015). Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Combination with Fludarabine and Cytarabine in Pediatric Patients with Relapsed or Refractory AML. Blood. 126(23). 1345–1345. 2 indexed citations

11.

Lund, Bente, Hanne Havsteen, Karin Leunen, et al.. (2015). Preliminary phase II results of selinexor, an oral selective inhibitor of nuclear export in patients with heavily pretreated gynecological cancers.. Journal of Clinical Oncology. 33(15_suppl). 5565–5565. 3 indexed citations

12.

Gounder, Mrinal M., Alona Zer, William D. Tap, et al.. (2015). A phase 1b study with selinexor, a first in class selective inhibitor of nuclear export (SINE) in patients with advanced sarcomas: An efficacy analysis.. Journal of Clinical Oncology. 33(15_suppl). 10569–10569. 2 indexed citations

13.

Lund, Bente, Hanne Havsteen, Tami Rashal, et al.. (2014). KCP-330-005/SIGN: A phase II, open-label study of efficacy and safety of the selective inhibitor of nuclear export (SINE) KPT-330 (SELINEXOR) in patients with advanced gynaecologic malignancies. International Journal of Gynecological Cancer. 29. 2 indexed citations

14.

Gutierrez, Martin, André Goy, John C. Byrd, et al.. (2014). A phase 1 dose-escalation study of the oral selective inhibitor of nuclear export (SINE) KPT-330 (selinexor) in patients (pts) with heavily pretreated non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology. 32(15_suppl). 8518–8518. 11 indexed citations

15.

Mau‐Sørensen, Morten, Albiruni R. Abdul Razak, Amit Mahipal, et al.. (2014). Safety and antitumor activity of selinexor (KPT-330), a first-in-class, oral XPO1 selective inhibitor of nuclear export: A phase I study expanded with colon cancer cohort.. Journal of Clinical Oncology. 32(3_suppl). 482–482. 7 indexed citations

16.

Gounder, Mrinal M., Herbert H. Loong, Yelena Ustoyev, et al.. (2014). A phase 1b food effect study of the first-in-class, oral, selective inhibitor of nuclear export (SINE) selinexor (KPT-330) in patients (pts) with advanced sarcomas.. Journal of Clinical Oncology. 32(15_suppl). 10587–10587. 1 indexed citations

17.

Kashyap, Trinayan, Marsha Crochiere, Sharon Friedlander, et al.. (2014). 247 Selective inhibitors of nuclear export (SINE) block the expression of DNA damage repair proteins and sensitize cancer cells to DNA damage therapeutic agents. European Journal of Cancer. 50. 83–83. 3 indexed citations

18.

Martignetti, John A., Albiruni R. Abdul Razak, Ying Chen, et al.. (2014). Preclinical and early clinical activity of the oral selective inhibitor of nuclear export (SINE) exportin 1 (XPO1) antagonist KPT-330 (Selinexor) in patients (pts) with platinum-resistant/refractory ovarian cancer (OvCa).. Journal of Clinical Oncology. 32(15_suppl). 5522–5522. 4 indexed citations

19.

Mahipal, Amit, Nashat Gabrail, Ammar Sukari, et al.. (2014). Clinical Activity of the Oral Selective Inhibitor of Nuclear Export (Sine) Selinexor (Kpt-330) in Patients with Head & Neck Squamos Cell Carcinoma (Hn-Scc). Annals of Oncology. 25. iv343–iv343. 3 indexed citations

20.

Rashal, Tami, Dilara McCauley, Maya Ilouze, et al.. (2013). Abstract 2075: Combination tTerapy KPT-SINE (selective inhibitors of nuclear export) with radiotherapy have additive effects in non-small cell lung cancer (NSCLC) cells in vitro and in vivo.. Cancer Research. 73(8_Supplement). 2075–2075. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact